Tiny study checks if novel bacterium is safe for people
NCT ID NCT07660107
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed trial tested whether a heat-killed bacterium called KGA-10 (also known as NeuroAlly) is safe and tolerable for healthy adults. Eight participants took either KGA-10 or a placebo daily for one week. Researchers tracked side effects and satisfaction using surveys. The study only looked at safety, not any health benefits.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Heat-killed Mycolicibacterium petrae KGA-10 (a type of bacterium, also called NeuroAlly)
- What this could lead to
- If safe, this could pave the way for future studies exploring whether KGA-10 has any health benefits.
- What could go wrong
- This was a very small, early safety study with only 8 people. It does not test whether KGA-10 helps any condition, and larger studies are needed to confirm safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
8 people
The number who actually took part.
- Started
-
Jul 2025
- Finished
-
Jul 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy individuals between the ages of 18 and 65 * Able to provide informed consent * Willing to take a daily supplement * Willing to complete at-home finger prick - blood spot samples on three occasions * English speaking Exclusion Criteria: * Inability to adequately respond to questions regarding the informed consent procedure * Currently involved in the criminal justice system as a prisoner or ward of the state * Non-English speaking * Current (past month) alcohol or substance abuse or dependence * Lifetime history of bipolar disorder or psychosis * Receiving intravenous, intramuscular, or oral antibiotics within the last month * Receiving medications that interfere with gut motility (opiates, loperamide, stool softeners) * Presence of central venous catheters (CVCs) * Gastrointestinal (GI) barriers as identified by the 2-week run-in period as determined by the study team (e.g., daily GI discomfort with frequent diarrhea prior to supplementation) * Participation in conflicting interventional research protocol * Vital signs outside of acceptable range (i.e., blood pressure \>160/100, oral temperature \>100°F, pulse \>100) * Use of any of the following drugs within the last 6 months: systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular, or oral); oral, intravenous, intramuscular, nasal or inhaled corticosteroids; cytokines or cytokine inhibitors; methotrexate or immunosuppressive cytotoxic agents * Acute disease at the time of enrollment (defer sampling until the participant recovers-acute disease is defined as the presence of a moderate or severe illness with or without fever) * Chronic, clinically significant (unresolved, requiring ongoing medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality * History of cancer except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision * Positive test for human immunodeficiency virus (HIV), Hepatitis B virus, or Hepatitis C virus * Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired) including HIV infection * Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time * Regular urinary incontinence necessitating use of incontinence protection garments * Female who is pregnant or lactating * Treatment for or suspicion of ever having had toxic shock syndrome * Those receiving immunosuppressive drugs or treatment including antineoplastic therapy, post-transplantation immunosuppressive therapy, and/or radiation therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Colorado, Boulder - WILD campus
Boulder, Colorado, 80301, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new cosmetic pass the skin allergy test?
- Can a new drug pair tame hodgkin lymphoma in older patients?
- Can a new injection shrink advanced solid tumors?
- Can a two-drug combo better tame prostate trouble?
- New vaginal capsule aims to tackle stubborn bacterial vaginosis
- New painkiller oliceridine tested against morphine in back surgery patients